Description

Human Immunoglobulin Injection 10% (3?ml:300?mg) is a highly purified intravenous solution containing human IgG antibodies at 100?mg/ml concentration. As a passive immunotherapy agent, it provides broad-spectrum, polyclonal antibodies derived from pooled donor plasma. Used in research to model immune protection, investigate antibody pharmacokinetics, and study mechanisms of immune modulation. Manufactured by Guangdong Danxia Biopharma Co., Ltd., under licence S20120022. Each vial delivers 300?mg IgG in 3?ml. Supplied exclusively for laboratory research use.

Product Specifications

Mechanism of Action & Research Applications

Human Immunoglobulin Injection 10% acts by providing exogenous IgG antibodies which bind and neutralize pathogens, modulate immune cell activation via Fc receptors, and support immune homeostasis. In research, this product is widely used in passive immunotherapy modeling, primary immunodeficiency simulations, antibody pharmacokinetics, and studies on immune modulation and autoimmunity. Ideal for preclinical or laboratory models investigating antibody-mediated protection and immunoregulation. For laboratory research use only.

Side Effects (For Reference Only in Models)

In experimental models or clinical analog sessions, potential observations may include local injection-site reactions, transient fever, headache, nausea, risk of thrombosis, renal function changes, hemolysis, and allergic-type responses. Higher risks observed in model systems include acute renal impairment or rare thrombotic events—use these observations to guide safe dosing and monitoring protocols. baxter.com

Disclaimer

Human Immunoglobulin Injection 10% (3?ml:300?mg) is intended strictly for laboratory research use only. Not for human or veterinary therapeutic or diagnostic use.